{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:43:00Z","timestamp":1794663780557,"version":"4.9.1"},"reference-count":151,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Measurable residual disease (MRD) monitoring has become a critical component in the management of acute myeloid leukemia (AML), to inform prognosis, guide therapy, and serve as a key end point in clinical trials. The 2025 update of the MRD guideline provides a comprehensive and refined framework for MRD assessment, aligned with the European LeukemiaNet (ELN) 2022 genetic risk classification. Developed by members of the ELN AML MRD Working Party, the guidelines incorporate expert consensus determined through a 2-stage Delphi round. They address the clinical implementation of MRD methodologies, technical considerations, integration into clinical trials, and future directions. Importantly, MRD recommendations are tailored to individual prognostic and genetic subgroups. A new qualitative MRD response category, designated as optimal, warning, or high risk of treatment failure, has been introduced to facilitate contextual interpretation of the MRD burden and its clinical relevance. Notably, ultrahigh-sensitivity next-generation sequencing\u2013based MRD assessment is now recommended for FLT3 internal tandem duplication\u2013mutated AML after intensive chemotherapy and before allogeneic hematopoietic cell transplantation. A total of 56 recommendations were formulated, with 53 achieving a high level of consensus (\u226590%). These updated guidelines represent a major step forward toward harmonizing MRD assessments in AML and enhancing its clinical utility across diverse treatment settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031480","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T21:35:45Z","timestamp":1765834545000},"page":"1147-1167","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9150-8026","authenticated-orcid":false,"given":"Jacqueline","family":"Cloos","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8857-9461","authenticated-orcid":false,"given":"Peter J. M.","family":"Valk","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1241-2048","authenticated-orcid":false,"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[{"name":"4Department of Medicine I, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany"},{"name":"5AgenDix GmbH, Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-9862","authenticated-orcid":false,"given":"Konstanze","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"},{"name":"8New York\u2013Presbyterian Hospital, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-3969","authenticated-orcid":false,"given":"Brent L.","family":"Wood","sequence":"additional","affiliation":[{"name":"9Hematopathology Division, University of Washington, Seattle, WA"},{"name":"10Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[{"name":"11Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"12Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA"},{"name":"13Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9385-9911","authenticated-orcid":false,"given":"Sa","family":"Wang","sequence":"additional","affiliation":[{"name":"14Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7909-457X","authenticated-orcid":false,"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Medical University of Lodz, Lodz, Poland"},{"name":"16Copernicus Memorial Multi-Specialist Oncology and Trauma Center, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"17Walter and Eliza Hall Institute of Medical Research, The University of Melbourne, Melbourne, Australia"},{"name":"18Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia"},{"name":"19Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6197-7091","authenticated-orcid":false,"given":"David","family":"Wu","sequence":"additional","affiliation":[{"name":"13Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-4404","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Vergez","sequence":"additional","affiliation":[{"name":"20Universit\u00e9 Toulouse III Paul Sabatier, Toulouse, France"},{"name":"21Cancer Research Center of Toulouse, UMR1037 INSERM, ERL5294 CNRS, Toulouse, France"},{"name":"22Laboratoire d'H\u00e9matologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0245-0553","authenticated-orcid":false,"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[{"name":"23Department of Biomedicine and Prevention, University of Rome tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7804-8643","authenticated-orcid":false,"given":"Bert A.","family":"van der Reijden","sequence":"additional","affiliation":[{"name":"24Department of Laboratory Medicine, Laboratory of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8311-983X","authenticated-orcid":false,"given":"Arjan A.","family":"van de Loosdrecht","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7417-4343","authenticated-orcid":false,"given":"Ing Soo","family":"Tiong","sequence":"additional","affiliation":[{"name":"25Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5848-6152","authenticated-orcid":false,"given":"Felicitas R.","family":"Thol","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-9469","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"27Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"},{"name":"28Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany"},{"name":"29Bavarian Cancer Research Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-1354","authenticated-orcid":false,"given":"Christophe","family":"Roumier","sequence":"additional","affiliation":[{"name":"30Laboratory of Hematology and Flow cytometry, CHU Lille, UMR9020 CNRS-UMR-S1277 INSERM, University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1346-6606","authenticated-orcid":false,"given":"Tom","family":"Reuvekamp","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"31Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-9546","authenticated-orcid":false,"given":"Claude","family":"Preudhomme","sequence":"additional","affiliation":[{"name":"30Laboratory of Hematology and Flow cytometry, CHU Lille, UMR9020 CNRS-UMR-S1277 INSERM, University of Lille, Lille, France"},{"name":"32Laboratoire de Biologie Mol\u00e9culaire, Centre Hospitalier R\u00e9gional Universitaire de Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-985X","authenticated-orcid":false,"given":"Adriana","family":"Plesa","sequence":"additional","affiliation":[{"name":"33Laboratory of Hematology and Flow cytometry, Lyon-Sud Hospital, HCL CHU Lyon, CRCL INSERM 1052\/CNRS 5286, University of Lyon, Hospices Civils de Lyon, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4971-3576","authenticated-orcid":false,"given":"Jad","family":"Othman","sequence":"additional","affiliation":[{"name":"34Northern Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia"},{"name":"35Department of Haematology, Royal North Shore Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5521-1337","authenticated-orcid":false,"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[{"name":"36Hematology and Stem Cell Transplantation Department and the Eisenberg RD Authority, Shaare Zedek Medical Center, Jerusalem, Israel"},{"name":"37Leukemia Service, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7848-9056","authenticated-orcid":false,"given":"Aguirre","family":"Mimoun","sequence":"additional","affiliation":[{"name":"38Laboratoire d'H\u00e9matologie, CHU Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7297-4988","authenticated-orcid":false,"given":"Luca","family":"Maurillo","sequence":"additional","affiliation":[{"name":"23Department of Biomedicine and Prevention, University of Rome tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7659-8879","authenticated-orcid":false,"given":"Agata","family":"Majchrzak","sequence":"additional","affiliation":[{"name":"39Department of Experimental Hematology, Copernicus Memorial Hospital, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-8467","authenticated-orcid":false,"given":"David","family":"de Leeuw","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-2874","authenticated-orcid":false,"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[{"name":"40MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-4911","authenticated-orcid":false,"given":"Dennis Dong Hwan","family":"Kim","sequence":"additional","affiliation":[{"name":"41Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada"},{"name":"42Department of Medicine, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-9696","authenticated-orcid":false,"given":"Maura R. V.","family":"Ikoma-Colturato","sequence":"additional","affiliation":[{"name":"43Flow Cytometry Laboratory, Hospital Amaral Carvalho, Ja\u00fa S\u00e3o Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2179-4870","authenticated-orcid":false,"given":"Lukas H.","family":"Haaksma","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9262-8246","authenticated-orcid":false,"given":"Monica L.","family":"Guzman","sequence":"additional","affiliation":[{"name":"7Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3986-6691","authenticated-orcid":false,"given":"Michaela","family":"Feuring","sequence":"additional","affiliation":[{"name":"6Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-1672","authenticated-orcid":false,"given":"Barbara","family":"Depreter","sequence":"additional","affiliation":[{"name":"44Department of Laboratory Medicine, AZ Delta General Hospital, Roeselare, Belgium"},{"name":"45Department of Haematology, Vrije Universiteit Brussel, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6641-0182","authenticated-orcid":false,"given":"Anna","family":"Czyz","sequence":"additional","affiliation":[{"name":"46Clinic of Hematology, Cellular Therapies and Internal Medicine, Wroc\u0142aw Medical University, Wroc\u0142aw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7391-7280","authenticated-orcid":false,"given":"Veit","family":"B\u00fccklein","sequence":"additional","affiliation":[{"name":"27Department of Medicine III, University Hospital, LMU Munich, Munich, Germany"},{"name":"29Bavarian Cancer Research Center, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-1551","authenticated-orcid":false,"given":"Constance","family":"Baer","sequence":"additional","affiliation":[{"name":"40MLL Munich Leukemia Laboratory, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-6193","authenticated-orcid":false,"given":"Costa","family":"Bachas","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Hematology Laboratories, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[{"name":"47School of Infection, Inflammation and Immunology, University of Birmingham College of Medicine and Health, Birmingham, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4320-9253","authenticated-orcid":false,"given":"Francesco","family":"Buccisano","sequence":"additional","affiliation":[{"name":"23Department of Biomedicine and Prevention, University of Rome tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6189-8067","authenticated-orcid":false,"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[{"name":"48Hourigan Lab, Fralin Biomedical Research Institute, Virginia Tech Fralin Biomedical Research Institute Cancer Research Center, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9333-5296","authenticated-orcid":false,"given":"Richard","family":"Dillon","sequence":"additional","affiliation":[{"name":"49Department of Medical and Molecular Genetics, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5318-9044","authenticated-orcid":false,"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[{"name":"26Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany"},{"name":"50Department of Internal Medicine IV, University Hospital Halle (Saale), Martin-Luther-University Halle-Wittenberg, Halle, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026031211215323100_bib1","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"2026031211215323100_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026031211215323100_bib3","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2026031211215323100_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"26","key":"2026031211215323100_bib5","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026031211215323100_bib6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"issue":"2","key":"2026031211215323100_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2022.280800","article-title":"Leukemic stem cells and therapy resistance in acute myeloid leukemia","volume":"108","author":"Stelmach","year":"2023","journal-title":"Haematologica"},{"issue":"5","key":"2026031211215323100_bib8","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/bloodadvances.2019001181","article-title":"Single-cell mutational profiling enhances the clinical evaluation of AML MRD","volume":"4","author":"Ediriwickrema","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026031211215323100_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"issue":"2","key":"2026031211215323100_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2026031211215323100_bib11","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1046\/j.1365-2648.2000.t01-1-01567.x","article-title":"Research guidelines for the Delphi survey technique","volume":"32","author":"Hasson","year":"2000","journal-title":"J Adv Nurs"},{"issue":"1","key":"2026031211215323100_bib12","doi-asserted-by":"crossref","first-page":"E676","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party","volume":"6","author":"Tettero","year":"2022","journal-title":"HemaSphere"},{"issue":"7","key":"2026031211215323100_bib13","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41375-024-02275-x","article-title":"Recommendations from the AML molecular MRD expert advisory board","volume":"38","author":"Scott","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2026031211215323100_bib36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2026031211215323100_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/bjh.18887","article-title":"A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure","volume":"202","author":"Sartor","year":"2023","journal-title":"Br J Haematol"},{"issue":"11","key":"2026031211215323100_bib14","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","article-title":"European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia","volume":"37","author":"Cross","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"2026031211215323100_bib15","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1002\/ajh.27087","article-title":"Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower intensity therapy: roadmap from an ELN-DAVID expert panel","volume":"98","author":"Ravandi","year":"2023","journal-title":"Am J Hematol"},{"issue":"5","key":"2026031211215323100_bib16","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/bloodadvances.2024014490","article-title":"Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML","volume":"9","author":"Vonk","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026031211215323100_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"issue":"14","key":"2026031211215323100_bib18","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/bloodadvances.2022009493","article-title":"Posttransplant MRD and T-cell chimerism status predict outcomes in patients who received allografts for AML\/MDS","volume":"7","author":"Loke","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026031211215323100_bib19","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","article-title":"The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia","volume":"20","author":"Buccisano","year":"2006","journal-title":"Leukemia"},{"issue":"31","key":"2026031211215323100_bib20","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1200\/JCO.2012.45.9628","article-title":"High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study","volume":"31","author":"Terwijn","year":"2013","journal-title":"J Clin Oncol"},{"issue":"32","key":"2026031211215323100_bib21","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2013.49.1753","article-title":"Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia","volume":"31","author":"Freeman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026031211215323100_bib22","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1200\/JCO.2017.76.3425","article-title":"Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations","volume":"36","author":"Freeman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"133","key":"2026031211215323100_bib23","first-page":"56386","article-title":"Comprehensive protocol to sample and process bone marrow for measuring measurable residual disease and leukemic stem cells in acute myeloid leukemia","author":"Cloos","year":"2018","journal-title":"J Vis Exp"},{"issue":"1","key":"2026031211215323100_bib24","first-page":"98","article-title":"Reporting blast percentage for response assessment in acute leukemias: recommendations from an EHA\/ELN expert panel","volume":"111","author":"Wang","year":"2024","journal-title":"Haematologica"},{"issue":"19","key":"2026031211215323100_bib25","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1 -mutated acute myeloid leukemia: a study from the German-Austrian Acute Myeloid Leukemia Study Group","volume":"29","author":"Kr\u00f6nke","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026031211215323100_bib26","doi-asserted-by":"crossref","first-page":"E408","DOI":"10.1002\/ajh.26698","article-title":"Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remission","volume":"97","author":"Short","year":"2022","journal-title":"Am J Hematol"},{"issue":"8","key":"2026031211215323100_bib27","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/s41375-024-02300-z","article-title":"Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillance","volume":"38","author":"McCarthy","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"2026031211215323100_bib28","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/s41375-023-01981-2","article-title":"Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms","volume":"37","author":"Shih","year":"2023","journal-title":"Leukemia"},{"issue":"12","key":"2026031211215323100_bib29","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood.2018886960","article-title":"GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia","volume":"134","author":"Venditti","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2026031211215323100_bib30","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/bloodadvances.2020003855","article-title":"Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial","volume":"5","author":"L\u00f6wenberg","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2026031211215323100_bib31","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3324\/haematol.2022.282639","article-title":"Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival","volume":"108","author":"Tettero","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"2026031211215323100_bib32","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12185-022-03441-6","article-title":"Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1","volume":"116","author":"Han","year":"2022","journal-title":"Int J Hematol"},{"issue":"19","key":"2026031211215323100_bib33","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026031211215323100_bib34","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1200\/JCO.24.00259","article-title":"Treatment intensification with either fludarabine, AraC, G-CSF and idarubicin, or cladribine plus daunorubicin and AraC on the basis of residual disease status in older patients with AML: results from the NCRI AML18 trial","volume":"43","author":"Russell","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"2026031211215323100_bib35","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1200\/JCO.2008.20.1533","article-title":"Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy","volume":"27","author":"Grimwade","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026031211215323100_bib37","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1200\/JCO.23.01599","article-title":"Targeting molecular measurable residual disease and low-blast relapse in AML with venetoclax and low-dose cytarabine: a prospective phase II study (VALDAC)","volume":"42","author":"Tiong","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026031211215323100_bib38","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/bloodadvances.2023011106","article-title":"Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML","volume":"8","author":"Jimenez-Chillon","year":"2024","journal-title":"Blood Adv"},{"issue":"9","key":"2026031211215323100_bib40","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41375-024-02335-2","article-title":"Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study","volume":"38","author":"Orvain","year":"2024","journal-title":"Leukemia"},{"issue":"5","key":"2026031211215323100_bib41","doi-asserted-by":"crossref","first-page":"e346","DOI":"10.1016\/S2352-3026(25)00037-7","article-title":"Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials","volume":"12","author":"Potter","year":"2025","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026031211215323100_bib42","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"2026031211215323100_bib43","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"issue":"12","key":"2026031211215323100_bib44","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026031211215323100_bib45","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/ajh.25211","article-title":"Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation","volume":"93","author":"Gilleece","year":"2018","journal-title":"Am J Hematol"},{"issue":"20","key":"2026031211215323100_bib46","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/bloodadvances.2025016306","article-title":"Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia","volume":"9","author":"Levis","year":"2025","journal-title":"Blood Adv"},{"issue":"26","key":"2026031211215323100_bib47","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026031211215323100_bib48","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","article-title":"Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial","volume":"10","author":"Xuan","year":"2023","journal-title":"Lancet Haematol"},{"issue":"15","key":"2026031211215323100_bib49","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1200\/JCO.23.02474","article-title":"Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3","volume":"42","author":"Levis","year":"2024","journal-title":"J Clin Oncol"},{"issue":"19","key":"2026031211215323100_bib50","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1182\/blood.2024025154","article-title":"Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML","volume":"145","author":"Levis","year":"2025","journal-title":"Blood"},{"issue":"suppl 1","key":"2026031211215323100_bib151","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1182\/blood-2024-207305","article-title":"Quantum-first: effects of Quizartinib (Q) on RFS, OS, CIR, and MRD in newly diagnosed (nd) patients (pts) with FMS-like tyrosine kinase 3-internal tandem duplication-positive (FLT3-ITD+) acute myeloid leukemia (AML) who received continuation (CONT) therapy (tx) [abstract]","volume":"144","author":"Levis","year":"2024","journal-title":"Blood"},{"issue":"14","key":"2026031211215323100_bib51","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1182\/blood.2021013404","article-title":"Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status","volume":"139","author":"Roboz","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2026031211215323100_bib52","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2026031211215323100_bib53","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/bloodadvances.2020003717","article-title":"Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia","volume":"5","author":"Maiti","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2026031211215323100_bib54","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1200\/JCO.21.01546","article-title":"Measurable residual disease response and prognosis in treatment-na\u00efve acute myeloid leukemia with venetoclax and azacitidine","volume":"40","author":"Pratz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026031211215323100_bib55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"issue":"7","key":"2026031211215323100_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"2026031211215323100_bib57","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"2026031211215323100_bib58","doi-asserted-by":"crossref","first-page":"5177","DOI":"10.1182\/bloodadvances.2025016399","article-title":"Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML","volume":"9","author":"Montesinos","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"2026031211215323100_bib59","doi-asserted-by":"crossref","first-page":"6942","DOI":"10.1038\/s41598-025-91936-7","article-title":"Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia","volume":"15","author":"de Azambuja","year":"2025","journal-title":"Sci Rep"},{"issue":"1","key":"2026031211215323100_bib60","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1002\/cpcy.73","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"issue":"suppl 1","key":"2026031211215323100_bib61","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1182\/blood-2023-181709","article-title":"The Laip-Based-Dfn approach is superior in terms of useful MRD results as compared to the Laip approach after cycle II in acute myeloid leukemia [abstract]","volume":"142","author":"Ngai","year":"2023","journal-title":"Blood"},{"issue":"5","key":"2026031211215323100_bib62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/cyto.b.22140","article-title":"Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal\/measurable residual disease detection","volume":"104","author":"Wang","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"5","key":"2026031211215323100_bib63","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.pathol.2019.03.010","article-title":"Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes","volume":"51","author":"Camburn","year":"2019","journal-title":"Pathology"},{"issue":"2","key":"2026031211215323100_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pathol.2019.09.021","article-title":"Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes","volume":"52","author":"Hanekamp","year":"2020","journal-title":"Pathology"},{"issue":"6","key":"2026031211215323100_bib65","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/bjh.17347","article-title":"Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia","volume":"192","author":"Loghavi","year":"2021","journal-title":"Br J Haematol"},{"issue":"1","key":"2026031211215323100_bib66","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cyto.b.22105","article-title":"Multicenter prospective evaluation of diagnostic potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS Flow Working Group","volume":"104","author":"Kern","year":"2023","journal-title":"Cytometry B Clin Cytom"},{"issue":"4","key":"2026031211215323100_bib67","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/ajcp\/aqac083","article-title":"Abnormal CD13\/HLA-DR expression pattern on myeloblasts predicts development of myeloid neoplasia in patients with clonal cytopenia of undetermined significance","volume":"158","author":"Jevremovic","year":"2022","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2026031211215323100_bib68","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/ajcp\/aqae187","article-title":"Flow cytometry evaluation of acute myeloid leukemia minimal residual disease based on an understanding of the normal maturation patterns in the blast compartments","volume":"163","author":"Roshal","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2026031211215323100_bib69","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41375-024-02158-1","article-title":"Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia","volume":"38","author":"Tettero","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026031211215323100_bib70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/cyto.b.21855","article-title":"Leukemia-associated immunophenotypes subdivided in \u201ccategories of specificity\u201d improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia","volume":"98","author":"Rossi","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"2026031211215323100_bib71","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02825-x","article-title":"Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry- based measurable residual disease assessment in acute myeloid leukemia","author":"Haaksma","year":"10  2025","journal-title":"Leukemia"},{"issue":"12","key":"2026031211215323100_bib72","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.3324\/haematol.2021.279777","article-title":"Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial","volume":"107","author":"Buccisano","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"2026031211215323100_bib73","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-024-02378-5","article-title":"Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)","volume":"38","author":"Rodr\u00edguez-Arbol\u00ed","year":"2024","journal-title":"Leukemia"},{"issue":"3","key":"2026031211215323100_bib74","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/ijlh.12068","article-title":"Technical issues: flow cytometry and rare event analysis","volume":"35","author":"Hedley","year":"2013","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"2026031211215323100_bib75","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3324\/haematol.2022.280747","article-title":"Delving the depths of measurable residual disease negativity in acute myeloid leukemia","volume":"107","author":"Freeman","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"2026031211215323100_bib76","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ccr.2010.12.012","article-title":"Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia","volume":"19","author":"Goardon","year":"2011","journal-title":"Cancer Cell"},{"issue":"1","key":"2026031211215323100_bib77","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cyto.b.22201","article-title":"The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells","volume":"108","author":"Reuvekamp","year":"2025","journal-title":"Cytometry B Clin Cytom"},{"issue":"8","key":"2026031211215323100_bib78","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1084\/jem.20151775","article-title":"Genetically distinct leukemic stem cells in human CD34-acute myeloid leukemia are arrested at a hemopoietic precursor-like stage","volume":"213","author":"Quek","year":"2016","journal-title":"J Exp Med"},{"issue":"5","key":"2026031211215323100_bib79","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/ijlh.14348","article-title":"Immunophenotypic features of early haematopoietic and leukaemia stem cells","volume":"46","author":"Reuvekamp","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"5","key":"2026031211215323100_bib80","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/s41375-018-0326-3","article-title":"CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia","volume":"33","author":"Zeijlemaker","year":"2019","journal-title":"Leukemia"},{"issue":"5","key":"2026031211215323100_bib81","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1182\/blood.2021014604","article-title":"An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026031211215323100_bib82","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41375-024-02148-3","article-title":"Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR","volume":"38","author":"Klyuchnikov","year":"2024","journal-title":"Leukemia"},{"issue":"21","key":"2026031211215323100_bib83","first-page":"2657","article-title":"Prospective validation of the prognostic relevance of CD34+CD38\u2013 AML stem cell frequency in the HOVON-SAKK132 trial","volume":"141","author":"Ngai","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026031211215323100_bib84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1182\/blood-2024-205457","article-title":"Flow MRD monitoring combining Laip\/Dfn and CD34+CD38- LSCs is a strong predictor of outcome in adult AML independently of the ELN-2022 risk: first results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network [abstract]","volume":"144","author":"Plesa","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026031211215323100_bib85","first-page":"2942","article-title":"Different features of acute myeloid leukemia stem cell quantification in intensively treated patients","volume":"110","author":"Ngai","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"2026031211215323100_bib86","first-page":"2877","article-title":"Leukemia stem cells in acute myeloid leukemia-mimicking \u201cspace and time continuum\u201d?","volume":"110","author":"Plesa","year":"2025","journal-title":"Haematol"},{"issue":"suppl 1","key":"2026031211215323100_bib87","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1182\/blood-2019-129866","article-title":"Flowsom: an R-based evaluation strategy for flow cytometry-based measurable residual disease (MRD) diagnostics in acute myeloid leukemia (AML) [abstract]","volume":"134","author":"B\u00fccklein","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2026031211215323100_bib88","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1038\/s41596-021-00550-0","article-title":"Analyzing high-dimensional cytometry data using FlowSOM","volume":"16","author":"Quintelier","year":"2021","journal-title":"Nat Protoc"},{"issue":"1","key":"2026031211215323100_bib89","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s43856-024-00700-x","article-title":"Computational assessment of measurable residual disease in acute myeloid leukemia using mixture models","volume":"4","author":"Mocking","year":"2024","journal-title":"Commun Med"},{"issue":"7","key":"2026031211215323100_bib90","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026031211215323100_bib91","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1097\/HS9.0000000000000173","article-title":"Innovation in flow cytometry analysis: a new paradigm delineating normal or diseased bone marrow subsets through machine learning","volume":"3","author":"Lacombe","year":"2019","journal-title":"HemaSphere"},{"issue":"10","key":"2026031211215323100_bib92","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1038\/s41375-025-02747-8","article-title":"Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial","volume":"39","author":"Mocking","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"2026031211215323100_bib93","doi-asserted-by":"crossref","first-page":"e70138","DOI":"10.1002\/hem3.70138","article-title":"Applications of machine learning for immunophenotypic measurable residual disease assessment in acute myeloid leukemia","volume":"9","author":"Mocking","year":"2025","journal-title":"HemaSphere"},{"issue":"10","key":"2026031211215323100_bib94","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cyto.a.24774","article-title":"Merging and imputation of flow cytometry data: a critical assessment","volume":"103","author":"Mocking","year":"2023","journal-title":"Cytometry A"},{"issue":"4","key":"2026031211215323100_bib95","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood.2020006219","article-title":"Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow","volume":"137","author":"Godwin","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026031211215323100_bib96","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.10432","article-title":"Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow","volume":"92","author":"Maurillo","year":"2007","journal-title":"Haematologica"},{"issue":"3","key":"2026031211215323100_bib97","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/leu.2015.255","article-title":"Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia","volume":"30","author":"Zeijlemaker","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2026031211215323100_bib98","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1080\/10428194.2019.1576868","article-title":"Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations","volume":"60","author":"Deng","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2026031211215323100_bib99","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1002\/hem3.141","article-title":"Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA","volume":"8","author":"Vonk","year":"2024","journal-title":"HemaSphere"},{"key":"2026031211215323100_bib100","first-page":"7386261:P432","article-title":"Validation of limit of quantification approach based flow cytometry for measurable residual disease assessment in acute myeloid leukemia in the HOVON-SAKK-132 trial","author":"Tettero","year":"2023","journal-title":"EHA Libr"},{"key":"2026031211215323100_bib101","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/bs.mcb.2024.02.022","article-title":"Spectral flow cytometry: fundamentals and future impact","volume":"186","author":"Robinson","year":"2024","journal-title":"Methods Cell Biol"},{"issue":"11","key":"2026031211215323100_bib102","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/cyto.a.24902","article-title":"Potential and challenges of clinical high-dimensional flow cytometry: a call to action","volume":"105","author":"Liechti","year":"2024","journal-title":"Cytometry A"},{"issue":"3","key":"2026031211215323100_bib103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/cyto.a.24811","article-title":"A 19-color single-tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia","volume":"105","author":"Fokken","year":"2024","journal-title":"Cytometry A"},{"issue":"5","key":"2026031211215323100_bib104","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.3390\/ijms25052847","article-title":"Phenotypic analysis of hematopoietic stem and progenitor cell populations in acute myeloid leukemia based on spectral flow cytometry, a 20-color panel, and unsupervised learning algorithms","volume":"25","author":"Matthes","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026031211215323100_bib105","doi-asserted-by":"crossref","first-page":"999163","DOI":"10.3389\/fimmu.2022.999163","article-title":"Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse","volume":"13","author":"Odak","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"2026031211215323100_bib106","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/cyto.b.22233","article-title":"28-color single tube for flow cytometric assessment of myeloid maturation, myeloid neoplasia, and acute myeloid leukemia minimal\/measurable residual disease","volume":"108","author":"Gao","year":"2025","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2026031211215323100_bib107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood-2012-10-461749","article-title":"The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML","volume":"122","author":"Shayegi","year":"2013","journal-title":"Blood"},{"issue":"26","key":"2026031211215323100_bib108","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1182\/blood.2020005998","article-title":"Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial","volume":"136","author":"Kapp-Schwoerer","year":"2020","journal-title":"Blood"},{"issue":"12","key":"2026031211215323100_bib109","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u201creal time\u201d quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer Program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"issue":"23","key":"2026031211215323100_bib110","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/bloodadvances.2021005455","article-title":"Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia","volume":"5","author":"Tiong","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"2026031211215323100_bib111","doi-asserted-by":"crossref","first-page":"e70198","DOI":"10.1002\/hem3.70198","article-title":"A pooled analysis of 3 large multicenter trials confirms a survival advantage for NPM1mut AML in MRDneg remission after intensive induction","volume":"9","author":"D\u00f6hner","year":"2025","journal-title":"HemaSphere"},{"issue":"6","key":"2026031211215323100_bib112","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2020.260133","article-title":"Minimal residual disease monitoring in acute myeloid leukemia with non-A\/B\/D NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use","volume":"106","author":"Lesieur","year":"2021","journal-title":"Haematologica"},{"issue":"12","key":"2026031211215323100_bib113","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2014-03-563403","article-title":"In adults with t(8;21)AML, posttransplant RUNX1\/RUNX1T1-based MRD monitoring, rather than c-KIT mutations, allows further risk stratification","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"19","key":"2026031211215323100_bib114","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"R\u00fccker","year":"2019","journal-title":"Blood"},{"issue":"10","key":"2026031211215323100_bib115","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41375-018-0086-0","article-title":"Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients","volume":"32","author":"H\u00f6llein","year":"2018","journal-title":"Leukemia"},{"issue":"3","key":"2026031211215323100_bib116","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3324\/haematol.2015.131946","article-title":"Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial","volume":"101","author":"Willekens","year":"2016","journal-title":"Haematologica"},{"issue":"14","key":"2026031211215323100_bib117","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1182\/blood-2012-06-435669","article-title":"Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial","volume":"120","author":"Yin","year":"2012","journal-title":"Blood"},{"issue":"23","key":"2026031211215323100_bib118","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1200\/JCO.2010.28.6468","article-title":"Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia","volume":"28","author":"Corbacioglu","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026031211215323100_bib119","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3324\/haematol.2019.235721","article-title":"Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia","volume":"106","author":"Puckrin","year":"2021","journal-title":"Haematologica"},{"issue":"11","key":"2026031211215323100_bib120","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1038\/s41409-021-01384-w","article-title":"Prognostic values of D816V KIT mutation and peri-transplant CBFB-MYH11 MRD monitoring on acute myeloid leukemia with CBFB-MYH11","volume":"56","author":"Cho","year":"2021","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"2026031211215323100_bib121","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood.2024024264","article-title":"Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML","volume":"144","author":"Cook","year":"2024","journal-title":"Blood"},{"issue":"11","key":"2026031211215323100_bib122","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.leukres.2012.07.001","article-title":"Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis","volume":"36","author":"Cornet","year":"2012","journal-title":"Leuk Res"},{"issue":"11","key":"2026031211215323100_bib123","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.leukres.2013.08.010","article-title":"Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1","volume":"37","author":"Pullarkat","year":"2013","journal-title":"Leuk Res"},{"issue":"6","key":"2026031211215323100_bib124","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"2026031211215323100_bib125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"29","key":"2026031211215323100_bib126","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO-25-00535","article-title":"Arsenic trioxide and all-trans retinoic acid combination therapy for the treatment of high-risk acute promyelocytic leukemia: results from the APOLLO Trial","volume":"43","author":"Platzbecker","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026031211215323100_bib127","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-025-01293-x","article-title":"Outcomes of acute myeloid leukemia with KMT2A (MLL) rearrangement: a multicenter study of TROPHY group","volume":"15","author":"Zhang","year":"2025","journal-title":"Blood Cancer J"},{"issue":"15","key":"2026031211215323100_bib128","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1182\/blood.2025029556","article-title":"Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML","volume":"146","author":"Othman","year":"2025","journal-title":"Blood"},{"issue":"22","key":"2026031211215323100_bib129","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1182\/blood.2022016567","article-title":"Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome","volume":"140","author":"Loo","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026031211215323100_bib130","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic value of FLT3-internal tandem duplication residual disease in acute myeloid leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026031211215323100_bib131","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1001\/jamaoncol.2024.0985","article-title":"Measurable residual FLT3 internal tandem duplication before allogeneic transplant for acute myeloid leukemia","volume":"10","author":"Dillon","year":"2024","journal-title":"JAMA Oncol"},{"issue":"10388","key":"2026031211215323100_bib132","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet (London, England)"},{"issue":"23","key":"2026031211215323100_bib133","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.1182\/bloodadvances.2024013758","article-title":"Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin","volume":"8","author":"R\u00fccker","year":"2024","journal-title":"Blood Adv"},{"key":"2026031211215323100_bib134","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016444","article-title":"FLT3-ITD measurable residual disease from the QuANTUM-First trial","author":"Levis","year":"6  2025","journal-title":"Blood Adv"},{"issue":"10","key":"2026031211215323100_bib135","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1038\/s41375-019-0483-z","article-title":"getITD for FLT3-ITD-based MRD monitoring in AML","volume":"33","author":"Bl\u00e4tte","year":"2019","journal-title":"Leukemia"},{"issue":"8","key":"2026031211215323100_bib136","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1182\/bloodadvances.2018015925","article-title":"A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations","volume":"2","author":"Levis","year":"2018","journal-title":"Blood Adv"},{"issue":"13","key":"2026031211215323100_bib137","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"2026031211215323100_bib138","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-02-829911","article-title":"Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML","volume":"132","author":"Thol","year":"2018","journal-title":"Blood"},{"issue":"10","key":"2026031211215323100_bib139","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/bloodadvances.2020003738","article-title":"Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML","volume":"5","author":"Tsai","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2026031211215323100_bib140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-021-00500-9","article-title":"Prognostic value of measurable residual disease monitoring by next-generation sequencing before and after allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"11","author":"Kim","year":"2021","journal-title":"Blood Cancer J"},{"issue":"9","key":"2026031211215323100_bib141","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"2026031211215323100_bib142","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood.2023022697","article-title":"Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation","volume":"144","author":"Wienecke","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2026031211215323100_bib143","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"issue":"2","key":"2026031211215323100_bib144","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41409-024-02447-4","article-title":"Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia","volume":"60","author":"Gui","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"19","key":"2026031211215323100_bib145","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/bloodadvances.2025016726","article-title":"Utility of IDH1\/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia","volume":"9","author":"Boertjes","year":"2025","journal-title":"Blood Adv"},{"issue":"5","key":"2026031211215323100_bib146","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/bjh.70135","article-title":"Monitoring of measurable residual disease by next-generation sequencing in patients with acute myeloid leukaemia","volume":"207","author":"Boudry","year":"2025","journal-title":"Br J Haematol"},{"issue":"25","key":"2026031211215323100_bib147","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1182\/blood-2018-10-880690","article-title":"Prognostic impact of circulating tumor DNA status post\u2013allogeneic hematopoietic stem cell transplantation in AML and MDS","volume":"133","author":"Nakamura","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2026031211215323100_bib148","doi-asserted-by":"crossref","first-page":"e70097","DOI":"10.1002\/hem3.70097","article-title":"Cell-free DNA for detection and monitoring of extramedullary AML relapse","volume":"9","author":"Hupe","year":"2025","journal-title":"HemaSphere"},{"key":"2026031211215323100_bib149","volume-title":"European Union. Regulation (EU) 2017\/746 of the European Parliament and of the Council of 5 April 2017 on In Vitro Diagnostic Medical Devices and Repealing Directive 98\/79\/EC and Commission Decision 2010\/227\/EU","year":"2017"},{"issue":"1","key":"2026031211215323100_bib150","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1038\/s41467-022-31397-y","article-title":"Ultra-sensitive monitoring of leukemia patients using superRCA mutation detection assays","volume":"13","author":"Chen","year":"2022","journal-title":"Nat Commun"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025031480\/2508905\/blood_bld-2025-031480-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025031480\/2508905\/blood_bld-2025-031480-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:22:13Z","timestamp":1773328933000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/11\/1147\/557333\/2025-update-on-MRD-in-acute-myeloid-leukemia-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":151,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031480","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,12]]},"published":{"date-parts":[[2026,3,12]]}}}